---
title: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
date: '2024-04-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38631003/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240418180510&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Adjuvant pembrolizumab was associated with a significant
  and clinically meaningful improvement in overall survival, as compared with placebo,
  among participants with clear-cell renal-cell carcinoma at increased risk for recurrence
  after surgery. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-564
  ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Adjuvant pembrolizumab was associated with a significant and clinically meaningful improvement in overall survival, as compared with placebo, among participants with clear-cell renal-cell carcinoma at increased risk for recurrence after surgery. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-564 ClinicalTrials.gov number, ...